002737 Sunflower Pharmaceutical Group
- 29.89
- -0.21-0.70%
Sunflower Pharmaceutical Group News
Sunflower Pharmaceutical Group (002737.SZ): Distribute 10 times 1.5 yuan for equity in 2023, with a registration date of June 13.
Sunflower Pharmaceutical Group (002737.SZ) announced on June 4th that the company's annual equity distribution plan for 2023 is: based on the current total share capital of the company, excluding 0 repurchased shares, 584,000,000 shares are used as the base, distributing 15.000000 yuan RMB cash (including tax) per 10 shares to all shareholders. The equity distribution record date for this time is June 13, 2024, and the ex-dividend date is June 14, 2024.
There's No Escaping Sunflower Pharmaceutical Group Co.,Ltd's (SZSE:002737) Muted Earnings
When close to half the companies in China have price-to-earnings ratios (or "P/E's") above 33x, you may consider Sunflower Pharmaceutical Group Co.,Ltd (SZSE:002737) as an attractive investment with i
China Grants Marketing Authorization to Sunflower Pharma's Electrolyte Powder for Constipation
China's medical products administrator granted marketing authorization to Sunflower Pharmaceutical (SHE:002737) subsidiary Harbin Sunflower Pharmaceutical's compound polyethylene glycol electrolyte po
Private Companies Account for 50% of Sunflower Pharmaceutical Group Co.,Ltd's (SZSE:002737) Ownership, While Individual Investors Account for 30%
Key Insights The considerable ownership by private companies in Sunflower Pharmaceutical GroupLtd indicates that they collectively have a greater say in management and business strategy 51% of the b
Sunflower Pharmaceutical (002737.SZ)'s net profit for the first quarter of 255 million yuan decreased 37.17% year over year
On April 25, Ge Longhui Pharmaceutical (002737.SZ) released its report for the first quarter of 2024. Operating income during the reporting period was 1,518 billion yuan, a year-on-year decrease of 14.01%; net profit attributable to shareholders of listed companies was 255 million yuan, a year-on-year decrease of 37.17%; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was 237 million yuan, a year-on-year decrease of 39.18%; and basic earnings per share were 0.44 yuan.
Should You Be Adding Sunflower Pharmaceutical GroupLtd (SZSE:002737) To Your Watchlist Today?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks' without any revenue, let alone profit. Unfortunately, these high risk investments
Sunflower Pharmaceutical (002737.SZ): OTC and CHC products currently account for a high share of revenue
Gelonghui, March 27丨An investor asked Sunflower Pharmaceutical (002737.SZ) on the investor interactive platform, “How much does the sum of the revenue of your physical pharmacy and internet pharmacy account for the total revenue?” The company replied that currently OTC and CHC products account for a high proportion of the company's revenue. For details, please check the company's annual report data.
Sunflower Pharmaceutical Group Co.,Ltd's (SZSE:002737) Stock Has Fared Decently: Is the Market Following Strong Financials?
Sunflower Pharmaceutical GroupLtd's (SZSE:002737) stock up by 3.8% over the past month. Given its impressive performance, we decided to study the company's key financial indicators as a company's lo
Sunflower Pharmaceutical GroupLtd (SZSE:002737) Stock Performs Better Than Its Underlying Earnings Growth Over Last Three Years
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But in contrast you can make much more than 100% if the company does well. F
Chinese Drug Regulator Accepts Application of Sunflower Pharma's Unit for Fexofenadine Hydrochloride Oral Suspension
China's National Medical Products Administration accepted the application of Sunflower Pharmaceutical Group's (SHE:002737) unit, Harbin Sunflower Pharmaceutical, to market its drug, fexofenadine hydro
Sunflower Pharmaceutical (002737.SZ): Fexofenadine hydrochloride oral suspension was approved for marketing
Gelonghui, Feb. 18: Sunflower Pharmaceutical (002737.SZ) announced that Harbin Sunflower Pharmaceutical Co., Ltd. (“Sunflower”), a wholly-owned subsidiary of the company, recently received a “Notice of Acceptance” issued by the State Drug Administration regarding the application for registration and marketing of fexofenadine hydrochloride oral suspension.
Individual Investors Own 30% of Sunflower Pharmaceutical Group Co.,Ltd (SZSE:002737) Shares but Private Companies Control 50% of the Company
Key Insights The considerable ownership by private companies in Sunflower Pharmaceutical GroupLtd indicates that they collectively have a greater say in management and business strategy 51% of the b
Here's Why We Think Sunflower Pharmaceutical GroupLtd (SZSE:002737) Might Deserve Your Attention Today
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story even if these companies are loss-making. Sometimes these stories can cloud the min
Wu Han of Zhongkang Technology: The key to solving the development problems of the traditional Chinese medicine industry is to break the “island effect”
The first Traditional Chinese Medicine Ecological Conference is expected to bring new opportunities and perspectives to enterprise development and industrial upgrading.
Is Sunflower Pharmaceutical Group Co.,Ltd's (SZSE:002737) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Most readers would already be aware that Sunflower Pharmaceutical GroupLtd's (SZSE:002737) stock increased significantly by 16% over the past three months. Given the company's impressive performance
Sunflower Pharmaceutical (002737.SZ): The company currently sells some agent varieties
Gelonghui November 3 | Sunflower Pharmaceutical (002737.SZ) stated on the investor interactive platform that from the perspective of improving the company's product structure, the company currently has some agent sales agents. The company will select varieties that are in line with the company's strategic layout and high product quality for cooperation, and continue to pay attention to product quality control risks during the cooperation.
[BT Financial Report Instantaneous Analysis] Sunflower Pharmaceutical's 2023 Three-Quarter Report: Significant performance growth, significant year-on-year increase in net profit
This earnings announcement time: 2023-10-25 16:16:34 Sunflower Pharmaceutical (stock code: 002737) is a leading company in the pharmaceutical industry. The company was founded in 2005 and is headquartered in China. As a comprehensive pharmaceutical company, Sunflower Pharmaceutical is committed to R&D, production and sales of innovative pharmaceuticals and medical devices. The company has a broad product line in various fields, including prescription drugs, non-prescription drugs, health products, and medical devices. The company's products cover many treatment fields, such as cardiovascular, digestive, nervous, respiratory, etc. Judging from the financial data,
Sunflower Pharmaceutical Group Co.,Ltd's (SZSE:002737) Market Cap Surged CN¥543m Last Week, Private Companies Who Have a Lot Riding on the Company Were Rewarded
Key Insights Significant control over Sunflower Pharmaceutical GroupLtd by private companies implies that the general public has more power to influence management and governance-related decisions 5
Sunflower Pharmaceutical (002737.SZ): Products sold contain roxithromycin and children's respiratory cold-related drugs
Glonghui, Oct. 23, 丨 Sunflower Pharmaceutical (002737.SZ) said on the investor interactive platform that the products sold by the company include roxithromycin, azithromycin, oral liquid/granules for children for pulmonary fever, cough, and wheezing, and pediatric Chai Gui antipyretic granules. For specific use, please follow the doctor's instructions.
Notice of acceptance of marketing approval for oseltamivir phosphate dry suspension, a subsidiary of Sunflower Pharmaceutical (002737.SZ)
Sunflower Pharmaceutical (002737.SZ) announced that Sunflower Pharmaceutical Group (Hengshui), a holding subsidiary of the company, has...
Analysis
Price Target
No Data
